Valuation: Alkem Laboratories Limited

Market Cap 622B 6.53B 5.88B 5.48B 4.97B 9.33B 9.39B 65.8B 25.69B 323B 24.53B 24B 1,038B P/E 2027 *
27.1x
P/E 2028 * 23.5x
Enterprise Value 609B 6.4B 5.75B 5.37B 4.86B 9.13B 9.19B 64.41B 25.15B 316B 24.02B 23.5B 1,016B EV / Sales 2027 *
3.65x
EV / Sales 2028 * 3.19x
Free-Float
38.59%
Yield 2027 *
0.97%
Yield 2028 * 1.07%
Sep. 24 Alkem Laboratories Limited Announces Resignation of Nitin Agrawal as Chief Financial Officer CI
Sep. 24 Alkem Laboratories Limited Announces Resignation of Nitin Agrawal as Key Managerial Personnel and Senior Management Personnel, Effective September 30, 2026 CI
Sep. 16 Alkem Laboratories Limited Launches Neuceno for the Treatment of Partial-Onset Seizures in Adult Patients CI
Sep. 15 Alkem Laboratories Limited Announces Appointment of Shubhadeep Sinha to Senior Management Position, Effective September 15, 2026 CI
Sep. 08 Alkem Laboratories Limited Launches Renocia Exo, India?s First Patented Ginsenoside Exosome-Based Hair Growth Serum CI
Aug. 14 Alkem Laboratories Limited, Q1 2027 Earnings Call, Aug 14, 2026
Aug. 14 Alkem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
Aug. 03 Alkem Laboratories Limited Announces Appointment of Rajpal Singh Rana to Senior Management Position, Effective August 03, 2026 CI
Jul. 23 Alkem Laboratories Limited Announces Resignation of Resignation of Jitendra Singh Huda as Senior Management Personnel, Effective from July 23, 2026 CI
Jun. 02 Alkem Laboratories Limited Launches Semaglutide in Single-Shot Pre-Filled Syringes At Price Starting Inr 350 CI
Jun. 02 Alkem Laboratories Shows Strong Moves But Weak Follow-Through Zonebourse
May. 29 Bob Capital Markets Downgrades Alkem Laboratories to Sell From Hold; Price Target is INR4,638 MT
May. 29 Jefferies Adjusts Alkem Laboratories' Price Target to INR6,500 From INR6,550, Keeps at Buy MT
1 day-0.93%
1 week-1.72%
Current month+0.73%
1 month+2.23%
3 months-6.57%
6 months-3.05%
Current year-5.55%
1 week 5,171
Extreme 5171
5,407
1 month 5,110
Extreme 5110
5,466.5
Current year 5,051
Extreme 5051
5,933.5
1 year 5,051
Extreme 5051
5,933.5
3 years 3,509.95
Extreme 3509.95
6,439.9
5 years 2,828
Extreme 2828
6,439.9
10 years 1,455
Extreme 1455
6,439.9
Manager TitleAgeSince
President - -
President - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 44 2013-08-08
Director/Board Member 63 2008-02-10
Director/Board Member 45 2019-11-10
Change 5-day change 1-year change 3-year change Capi.($)
-0.93%-1.72%-5.31%+43.97% 6.61B
+3.95%+2.02%+49.29%+96.68% 1,040B
+1.97%-2.03%+32.67%+60.73% 599B
+3.80%+5.04%+24.41%+93.61% 485B
+3.71%+3.02%+73.67%+41.25% 350B
+3.09%+3.03%+29.59%+47.09% 345B
+2.82%+2.20%+17.90%+40.67% 272B
+3.40%+0.99%-3.44%+12.10% 244B
+3.65%+3.44%+45.41%+48.95% 223B
+3.83%+4.57%+29.61%+93.90% 183B
Average +2.89%+2.06%+29.38%+57.89% 374.94B
Weighted average by Cap. +3.31%+2.30%+36.87%+68.14%

Financials

2027 *2028 *
Net sales 167B 1.75B 1.58B 1.47B 1.33B 2.5B 2.52B 17.67B 6.9B 86.65B 6.59B 6.44B 279B 186B 1.95B 1.76B 1.64B 1.49B 2.79B 2.81B 19.68B 7.69B 96.54B 7.34B 7.18B 310B
Net income 23.15B 243M 219M 204M 185M 347M 349M 2.45B 956M 12.01B 913M 893M 38.64B 27.28B 287M 258M 240M 218M 409M 412M 2.89B 1.13B 14.16B 1.08B 1.05B 45.53B
Net Debt -13.12B -138M -124M -116M -105M -197M -198M -1.39B -542M -6.81B -518M -507M -21.91B -28.19B -296M -266M -249M -225M -423M -425M -2.98B -1.16B -14.63B -1.11B -1.09B -47.05B
Projected Income Statement - Annual - Alkem Laboratories Limited
Logo Alkem Laboratories Limited
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Employees
19,346
Date Price Change Volume
26-10-14 ₹5,201.00 -0.93% 79,840
26-10-13 ₹5,250.00 +0.86% 103,084
26-10-12 ₹5,205.00 -1.40% 179,595
26-10-09 ₹5,279.00 +0.56% 96,074
26-10-08 ₹5,249.50 -1.89% 281,234
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Alkem Laboratories Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
5,201.00INR
Average target price
6,002.55INR
Spread / Average Target
+15.41%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alkem Laboratories Limited
  1. Stock Market
  2. Stocks
  3. ALKEM Stock